Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK7 | P49862 | 1/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | ACE | P12821 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.38 |
| ▸ | MMP1 | P03956 | 1/20 | 0.38 |
| ▸ | MMP3 | P08254 | 1/20 | 0.38 |
| ▸ | MMP7 | P09237 | 1/20 | 0.38 |
| ▸ | MMP13 | P45452 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | STS | P08842 | 1/20 | 0.38 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.37 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.37 |
| ▸ | YAP1 | P46937 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20741005 | 1.00 | KLK7 (0.44) | KLK7HSD11B1HDAC8NPC1RAB9A | |
| SCHEMBL20741003 | 1.00 | KLK7 (0.44) | KLK7HSD11B1HDAC8NPC1RAB9A | |
| SCHEMBL19245206 | 0.92 | KLK7 (0.43) | KLK7HSD11B1HDAC8NPC1RAB9A | |
| SCHEMBL4943086 | 0.90 | MMP1 (0.44) | KLK7HSD11B1HDAC8NPC1RAB9A | |
| SCHEMBL4943089 | 0.90 | MMP1 (0.44) | KLK7HSD11B1HDAC8NPC1RAB9A | |
| SCHEMBL25523663 | 0.86 | FKBP1A (0.50) | KLK7HSD11B1FKBP1A | |
| SCHEMBL7215367 | 0.83 | ATM (0.38) | KLK7HSD11B1MMP1MMP3MMP7 | |
| SCHEMBL4941806 | 0.80 | MMP1 (0.41) | HDAC8MMP1MMP3MMP7MMP13 | |
| SCHEMBL4941809 | 0.80 | MMP1 (0.41) | HDAC8MMP1MMP3MMP7MMP13 | |
| SCHEMBL27534101 | 0.79 | ESR2 (0.47) | HSD11B1NPC1RAB9AGPR119STS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3411359-B1 | METHODS OF PREPARING HYDROXYLAMINE DERIVATIVES USEFUL IN THE PREPARATION OF ANTI-INFECTIVE AGENTS | MERCK SHARP & DOHME (US) | 2021-10-13 | — | — | EP | disclosed |
| US-10472345-B2 | Methods of preparing hydroxylamine derivatives useful in the preparation of anti-infective agents | MERCK SHARP & DOHME CORP. (US) | 2019-11-12 | — | — | US | disclosed |
| US-20190055216-A1 | METHODS OF PREPARING HYDROXYLAMINE DERIVATIVES USEFUL IN THE PREPARATION OF ANTI-INFECTIVE AGENTS | MERCK SHARP & DOHME CORP. (US) | 2019-02-21 | — | — | US | disclosed |
| EP-3411359-A1 | METHODS OF PREPARING HYDROXYLAMINE DERIVATIVES USEFUL IN THE PREPARATION OF ANTI-INFECTIVE AGENTS | Merck Sharp & Dohme Corp. (US) | 2018-12-12 | — | — | EP | disclosed |
| WO-2017136254-A1 | METHODS OF PREPARING HYDROXYLAMINE DERIVATIVES USEFUL IN THE PREPARATION OF ANTI-INFECTIVE AGENTS | MERCK SHARP & DOHME CORP. (US) | 2017-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190055216-A1 | METHODS OF PREPARING HYDROXYLAMINE DERIVATIVES USEFUL IN THE PREPARATION OF ANTI-INFECTIVE AGENTS | HAAO, OGA, HNMT | KLK7 2892/4885HSD11B1 1536/4885HDAC8 647/4885 |
| US-10472345-B2 | Methods of preparing hydroxylamine derivatives useful in the preparation of anti-infective agents | HAAO, OGA, HNMT | KLK7 2892/4885HSD11B1 1536/4885HDAC8 647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.